Prolastin Related Published Studies
Well-designed clinical trials related to Prolastin (Alpha 1-Antitrypsin)
The fibrinogen cleavage product Aalpha-Val360, a specific marker of neutrophil elastase activity in vivo. [2011.08]
Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessments. [2010.12]
Pharmacokinetic comparability of Prolastin(R)-C to Prolastin(R) in alpha-antitrypsin deficiency: a randomized study. [2010.09.30]
Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. [2009.06]
Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma--results from the ALA-ACRC low-dose theophylline trial. [2007.10]
Alpha-1-antitrypsin replacement therapy: current status. [2006.03]
Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. [2006.03]
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. [2006.02]
Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency. [2005.05.31]
Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome? [2005]
Prevalence of alpha1-antitrypsin phenotypes in patients with IgA nephropathy. [2004.12]
Protease inhibitors alpha1-antitrypsin and ilomastat are not ototoxic in the chinchilla. [2003.10]
Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices. [2003.08]
Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. [2002.07]
Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. [2001.03]
Alpha-1 proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants. [2001]
Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. [2000.03]
A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. [1999.11]
Functional and antigenic concentrations of alpha-1-proteinase inhibitor after administration for the prevention of chronic lung disease of prematurity. [1999.09]
alpha1-Proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial. [1998.01]
Progress of emphysema in severe alpha 1-antitrypsin deficiency as assessed by annual CT. [1997.09]
Efficacy of systemically administered acetylsalicylic acid plus scaling on periodontal health and elastase-alpha 1-proteinase inhibitor in gingival crevicular fluid. [1996.03]
Effects of low dose methotrexate therapy on the concentration and the glycosylation of alpha 1-acid glycoprotein in the serum of patients with rheumatoid arthritis: a longitudinal study. [1994.12]
Well-designed clinical trials possibly related to Prolastin (Alpha 1-Antitrypsin)
Impact of non-linear smoking effects on the identification of gene-by-smoking interactions in COPD genetics studies. [2011.10]
Perioperative use of a neutrophil elastase inhibitor in video-assisted thoracoscopic oesophagectomy for cancer. [2011.07]
Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. [2010.12.22]
Blood folate status and expression of proteins involved in immune function, inflammation, and coagulation: biochemical and proteomic changes in the plasma of humans in response to long-term synthetic folic acid supplementation. [2010.04.05]
Pro- and prebiotic supplementation induces a transient reduction in hemoglobin concentration in infants. [2009.11]
Pro- and Prebiotic Supplementation Induces a Transient Reduction in Hemoglobin Concentration in Infants. [2009.07.28]
Alterations in the human lung proteome with lipopolysaccharide. [2009.05.11]
The benefit of daily photoprotection. [2008.05]
No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. [2006.07]
Rectal bleeding in infancy: clinical, allergological, and microbiological examination. [2006.04]
Effects of ulinastatin on pulmonary artery pressure during abdominal aortic aneurysmectomy. [2006.02]
Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. [2005.02]
Residues 34-39 in the thyrotropin receptor are not the target of autoantibodies from sera of patients with Graves' disease. [2004.08]
Tissue trauma after vaginal hysterectomy and colporrhaphy versus abdominal hysterectomy: a randomised controlled study. [2004.08]
Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. [2004.03]
Effect of early enteral nutrition on intestinal permeability, intestinal protein loss, and outcome in dogs with severe parvoviral enteritis. [2003.11]
The value of routine antibiotic prophylaxis in mandibular third molar surgery: acute-phase protein levels as indicators of infection. [2001.06]
Tension-free hernia repair is associated with an increase in inflammatory response markers against the mesh. [2000.09]
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. [2000.07]
Treatment of iron deficiency anemia and associated protein-losing enteropathy in children. [2000.01]
Activation of the contact system of coagulation does not contribute to the hemostatic imbalance in hypertriglyceridemia. [1999.10]
Reducing neutrophil elastase-induced lung injury. [1999.03]
Inhaled budesonide in ventilator-dependent preterm infants: a randomized, double-blind pilot study. [1999]
Activation of the protein C system during cardiopulmonary bypass with and without aprotinin. [1998.12]
Peritoneal lavage with aprotinin in patients with severe acute pancreatitis. Effects on plasma and peritoneal levels of trypsin and leukocyte proteases and their major inhibitors. [1998.08]
Steroids in the hemolytic uremic syndrome. [1998.02]
Probiotics: a novel approach in the management of food allergy. [1997.02]
Ozone exposure has both a priming effect on allergen-induced responses and an intrinsic inflammatory action in the nasal airways of perennially allergic asthmatics. [1995.05]
Local serum application: restoration of sufficient host defense in human peritonitis. [1994.01]
Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. [1994.01]
Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. [1993.06]
The effect of bed rest and intra-articular steroids on the acute phase response in rheumatoid arthritis. [1993.01]
The effect of epidural blockade on postoperative hypercoagulability following abdominal aortic bypass surgery. [1992.11]
The influence of tourniquet ischaemia on post-operative degranulation of polymorphonuclear granulocytes. [1992.05]
Attenuation of intra-operative surgical stress response has no influence on post-operative degranulation of polymorphonuclear granulocytes. [1991.09]
Effect of dexamethasone on pulmonary inflammation and pulmonary function of ventilator-dependent infants with bronchopulmonary dysplasia. [1991.05]
Comparison of the clinical performance, contraceptive efficacy and acceptability of levonorgestrel-releasing IUD and Norplant-2 implants in China. [1990.05]
Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration. [1988.02]
Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. [1987.10]
Other research related to Prolastin (Alpha 1-Antitrypsin)
Relation of functional characteristics and serum alpha-1-antitrypsin (AAT) concentration in patients with PiMM phenotype and chronic obstructive pulmonary disease (COPD). [2011.12]
ANCA-associated vasculitis is linked to carriage of the Z allele of alpha antitrypsin and its polymers. [2011.10]
Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing alpha(1)-Antitrypsin: Interim Results. [2011.10]
A Review of Alpha-1 Antitrypsin Deficiency. [2011.09.29]
Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. [2011.08]
Oxidation of Z alpha1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. [2011.08]
The prevalence of alpha-1 antitrypsin deficiency in Ireland. [2011.07.13]
The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and alpha-1 anti-trypsin deficiency. [2011.06]
Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema. [2011.04.12]
[Clinical trial endpoints in alpha-1-antitrypsin deficiency: interdisciplinary aspects]. [2011.04]
Matrix metalloproteinase-9 predicts pulmonary status declines in alpha1-antitrypsin deficiency. [2011.03.23]
The role of augmentation therapy in alpha-1 antitrypsin deficiency. [2011.03]
Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. [2011.02.24]
[Practical applications of recombinant alpha-1-antitrypsin in medicine]. [2010.12]
Emerging drugs for alpha-1-antitrypsin deficiency. [2010.12]
Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI) - problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosis. [2010.11.04]
Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. [2010.10.05]
Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. [2010.09]
Outdoor air pollution is associated with rapid decline of lung function in alpha-1-antitrypsin deficiency. [2010.08]
An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. [2010.07.09]
Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. [2010.07.07]
Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy. [2010.07]
Culture of impure human islet fractions in the presence of alpha-1 antitrypsin prevents insulin cleavage and improves islet recovery. [2010.07]
Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. [2010.06]
Laboratory testing of individuals with severe alpha1-antitrypsin deficiency in three European centres. [2010.05]
alpha 1-antitrypsin enhances insulin secretion and prevents cytokine-mediated apoptosis in pancreatic beta-cells. [2010.05]
Studies of gamma-glutamyl transferase in alpha-1 antitrypsin deficiency. [2010.04]
The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation. [2010.04]
Alpha 1 Antitrypsin Deficiency in Children with Chronic Liver Disease in North India. [2010.03.15]
Alpha-1-antitrypsin deficiency and smoking as risk factors for mismatch repair deficient colorectal cancer: a study from the colon cancer family registry. [2010.02]
Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. [2010.01]
Alpha1-antitrypsin deficiency: forgotten etiology. [2010]
Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV
combination therapy. [2010]
[Update: Alpha-1-antitrypsin deficiency. Summary of a scientific symposium at the conference of the Swiss Pneumologic Society on April 16th, 2009] [2009.12]
Quantitative airway assessment on computed tomography in patients with alpha1-antitrypsin deficiency. [2009.12]
Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options? [2009.11]
Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options? [2009.10.15]
alpha1-Antitrypsin deficiency: best clinical practice. [2009.10]
Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy. [2009.09.29]
|
